German startup jumps into the hot radiopharma space with a former Ipsen compound as lead program

Tyler Patchen

News Reporter

Radiopharmaceuticals are continuing to become a hot topic in biopharma, with companies such as Sequoia, Novartis and Bristol Myers Squibb looking to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

German startup jumps into the hot radiopharma space with a former Ipsen compound as lead program

Tyler Patchen

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Ger­man start­up jumps in­to the hot ra­dio­phar­ma space with a for­mer Ipsen com­pound as lead pro­gram

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

German startup jumps into the hot radiopharma space with a former Ipsen compound as lead program